OPPORTUNITIES RESORPTION GOUTY TOPHI DURING URATE-LOWERING THERAPY: CLINICAL CASE

Tripolka S.A.¹, Golovach I.Yu.²

• ¹Коммунальное учреждение здравоохранения «Областная клиническая больница — центр экстренной медицинской помощи и медицины катастроф», Харьков
• ²Feofaniya Clinical Hospital, Kyiv

Summary. It is known that tophi are formed by the «natural» course of gout, and the absence of adequate urate-lowering therapy after an average of 7–10 years from the onset of the disease, the frequency of detection of up to 34% and increases the duration of illness in parallel. Urate-lowering therapy is used to initially reduce and control the levels of uric acid, and to remove sediment deposits crystals in the tissues of patients with chronic gout. In recent years, there is evidence of possible resorption of tophi, until they are completely dissolved by careful monitoring of serum uric acid levels and adequate assignment urate-lowering drugs. The time required to dissolve the crystals deposits due to the duration of the disease, the overall load of the crystal and the achieved level of uric acid. The clinical observation of reducing the size of tophi in patients with severe tophaceous gout after replacing allopurinol to febuxostat and achieve target levels of serum uric acid are presented.